Up 90% in 2 weeks, here's why the Paradigm share price has been halted

The biopharmaceutical company is planning a capital raise.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Paradigm share price has been frozen today
  • The biopharmaceutical company has requested a trading halt pending a capital raising announcement
  • Paradigm has a number of research initiatives on the go

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt. 

The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday's close, a gain of 89.5%. 

Across this timeframe, the ASX-listed biopharmaceutical company released its quarterly results for the three months ended 30 June 2022 and announced the results of a major research project.

Before market open this morning, it entered a trading halt pending an announcement relating to a capital raising.

Let's dive deeper to get up to speed with what's happening at Paradigm. 

Female doctor with a mask holds out hand in a stop gesture.

Image source: Getty Images

Why is Paradigm in a trading halt?

The Paradigm share price has been frozen today after the company requested a trading halt in relation to a capital raising.

It will remain halted until the start of normal trading on Monday or when the announcement is released to the market, whichever comes first.

The company burned $32 million of cash for FY22 and the cash balance at 31 December 2021 was nearly $55 million. It seems Paradigm wants to solidify its capital base to progress the research initiatives outlined below. 

In its last announcement on Monday, Paradigm reported it will be presenting the results of its drug development to treat the metabolic disease mucopolysaccharidoses (MPS) type I in February next year. 

Paradigm's long-term goal is to develop an injectable form of pentosan polysulfate sodium (PPS) to treat MPS. Historically, PPS has primarily been used to assist with bladder pain.

In addition, Paradigm is researching the use of PPS for a range of other clinical uses, such as treating pain in patients suffering from musculoskeletal disorders. 

Paradigm share price snapshot

The Paradigm share price is up 45% in the last six months and 87% over the past month. It has also gained 4% this year to date.

In contrast, the S&P/ASX 200 Index (ASX: XJO) has declined by 2% across the last six months and 7% year to date, but is up almost 7% in the past month.

The recent rapid rally in the Paradigm share price has been spurred by some positive developments. However, investors should be aware that Paradigm's net loss has been on a downward trend from FY17 to FY21.

The recent momentum has driven Paradigm's market capitalisation to around $450 million.

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

Group of investors madly grabbing for cash on city street.
Capital Raising

This ASX stock is tumbling 10% after huge 640% run. Here's why

Investors are selling this ASX stock after a massive run.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Capital Raising

Guess which ASX stock is crashing 18% today

Investors are losing patience with this ASX stock.

Read more »

Close-up photo of a human hand with $100 bills offering the money to another human hand.
Capital Raising

Why is this ASX stock crashing 20% today?

This ASX stock is among today’s biggest fallers.

Read more »

A group of hands up in the air as if signifying a hearty vote in favour of a motion.
Capital Raising

EOS shares are sliding again. Here's what investors are worried about

EOS shares are falling despite strong demand for its discounted SPP.

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Technology Shares

'Game on!' Why Megaport shares are rocketing 27% today

This tech stock is ending the week with a bang. Let's find out why.

Read more »

Military engineer works on drone.
Capital Raising

EOS shares halted after huge run as $175 million raising lands

EOS investors have plenty to watch tomorrow.

Read more »

A young woman's hands are shown close up with many blingy gold rings on her fingers and two large gold chains around her neck with dollar signs on them.
Capital Raising

Why BWP shares are back in the red today

BWP shares fall after completing an institutional offer.

Read more »

Close-up photo of a human hand with $100 bills offering the money to another human hand.
Capital Raising

Why this ASX stock just jumped 7% after a 70% run

Navigator shares surge after a capital raising update.

Read more »